Toregem BioPharma has secured $5.3 million to advance its experimental tooth-regeneration drug, TRG035, into Phase II clinical trials. The ...

India faces a challenging global economic outlook for 2026-27. Geopolitical tensions and volatile oil prices are key concerns. However, Ind...

Bernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future g...

Biocon's fourth-quarter net profit saw a significant drop of 63 percent year-on-year. This decline was attributed to exceptional charges im...

Biocon Ltd reported a 56.8% drop in Q4 net profit to Rs 198.6 crore, impacted by an Rs 80.4 crore exceptional item. Despite this, consolida...

Moderna had earlier posted a loss of $2.52 per share a year earlier, while analysts expected a loss of $3.96 per share.

India Pharma Conference: India is set to become a global leader in advanced medicines like biologics and biosimilars, Union Minister J P Na...

Sun Pharmaceutical Industries is nearing a $12 billion acquisition of Organon & Co, marking its most significant overseas expansion. Follow...

Markets surged for the fourth consecutive session, buoyed by favorable geopolitical cues. Key stocks like TCS, HDFC Bank, ITC Hotels, Hyund...

Union Budget 2026: With the announcement of the 'Biopharma Shakti' initiative, India is gearing up to take the world stage in biopharmaceut...

The proposed fund aims to position India as a global biopharma manufacturing hub

Union Budget 2026: Finance Minister Nirmala Sitharaman has presented a six-point plan to boost India's economy. The strategy prioritizes ma...

The joint report by the USA India Chamber of Commerce & PwC India titled, “Clinical Trial opportunities in India” which will be released at...

Hyderabad, Dec 9- Prestige BioPharma Ltd, a Singapore-based firm and Dr. Reddy's Laboratories Ltd., on Thursday announced that the two comp...

The Bengaluru-based company has spent Rs 47 crore on R&D in the third quarter of this fiscal, an increase of 124 per cent over the correspo...

With the snapping of ties, the Indian biotech company has limited options for growth of its insulin especially in regulated markets.

Intas Biopharmaceutical Ltd, a group company of the Rs 1,600-crore Intas Pharmaceuticals Ltd, would soon enter into an out-licensing and su...